Latest News

New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.

Health systems coordinate pharmacy, payers, clinicians, labs, and electronic health record (EHR) teams to deliver ultra-high-cost gene therapies.

Pembrolizumab neoadjuvant immunotherapy hits ~70% complete responses in desmoplastic melanoma.

Phase 4 data show suzetrigine controls post–plastic surgery pain, keeping nearly 91% of patients opioid-free with good pain ratings and tolerability.

A Baptist Health pharmacy expert shares real-world myelofibrosis oncology tips on JAK selection, symptom control, and navigating specialty drug costs.

FDA approval expands teclistamab plus daratumumab significantly improved survival in the MajesTEC-3 trial.

Meta-analysis finds insulin efsitora provides similar glycemic control with superior hemoglobin A1C reduction at 52 weeks and lower total weekly insulin dose, while maintaining an acceptable safety profile.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.

New research links long COVID taste loss to impaired sweet-bitter-umami signaling, guiding pharmacists on nutrition risks and emerging therapies.

Long-term care pharmacies optimize medication, vaccines, and safer therapies to boost patient care, cut risks, and navigate Medicare barriers.

RSV vaccines cut hospitalization risk—and may lower dementia risk.

Navepegritide becomes the first and only once-weekly treatment to increase linear growth in children with achondroplasia.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Launching sustainable, effective CGT programs requires a road map for strategy, operations, access, finance, quality, and pharmacy.

Milsaperidone is indicated for acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia in adults.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.

Pegvaliase becomes the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in patients with phenylketonuria.